Proton magnetic resonance spectroscopy in schizophrenia.

Proton magnetic resonance spectroscopy (MRS) has become an important tool to study in vivo certain biochemical aspects of brain disorders. In the last decade this technique has been applied to the in vivo investigation of pathophysiological aspects of psychiatric disorders, extending knowledge of the related brain alterations. This review will focus on providing some background to clarify technical and biochemical issues and it will describe the studies that have been performed in schizophrenia. The results will be framed in a more general context to highlight what we have learned and what remains to be understood from the application of this technique to schizophrenia.

[1]  R. Saunders,et al.  The relationship between dorsolateral prefrontal N-acetylaspartate measures and striatal dopamine activity in schizophrenia∗ ∗ See accompanying Editorial, in this issue. , 1999, Biological Psychiatry.

[2]  Karl Herholz,et al.  Localization of Language-Related Cortex with15O-Labeled Water PET in Patients with Gliomas , 1998, NeuroImage.

[3]  J. Levitt,et al.  Preliminary study of frontal lobe 1H MR spectroscopy in childhood‐onset schizophrenia , 1998, Journal of magnetic resonance imaging : JMRI.

[4]  P. Renshaw,et al.  Proton magnetic resonance spectroscopy of the temporal lobes in schizophrenics and normal controls , 1996, Schizophrenia Research.

[5]  P M Matthews,et al.  Normalization of neuronal metabolic dysfunction after surgery for temporal lobe epilepsy , 1997, Neurology.

[6]  D. Gadian,et al.  Proton nuclear magnetic resonance spectroscopy unambiguously identifies different neural cell types , 1993, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[7]  P. Matthews,et al.  Chemical pathology of acute demyelinating lesions and its correlation with disability , 1995, Annals of neurology.

[8]  C. Heimberg,et al.  Regional proton magnetic resonance spectroscopy in schizophrenia and exploration of drug effect , 1998, Psychiatry Research: Neuroimaging.

[9]  J H Duyn,et al.  Multisection proton MR spectroscopic imaging of the brain. , 1993, Radiology.

[10]  D Shedid,et al.  MRS Metabolic Markers of Seizures and Seizure‐Induced Neuronal Damage , 1998, Epilepsia.

[11]  Alessandro Bertolino,et al.  Regionally Specific Neuronal Pathology in Untreated Patients with Schizophrenia: A Proton Magnetic Resonance Spectroscopic Imaging Study , 1998, Biological Psychiatry.

[12]  Corey C. Ford,et al.  Frontal lobe of children with schizophrenia spectrum disorders: A proton magnetic resonance spectroscopic study , 1998, Biological Psychiatry.

[13]  G Tedeschi,et al.  Regionally specific pattern of neurochemical pathology in schizophrenia as assessed by multislice proton magnetic resonance spectroscopic imaging. , 1996, The American journal of psychiatry.

[14]  G J Barker,et al.  Proton magnetic resonance spectroscopy: an in vivo method of estimating hippocampal neuronal depletion in schizophrenia , 1995, Psychological Medicine.

[15]  R W Neufeld,et al.  Measurement of glutamate and glutamine in the medial prefrontal cortex of never-treated schizophrenic patients and healthy controls by proton magnetic resonance spectroscopy. , 1997, Archives of general psychiatry.

[16]  M. A. Samphilipo,et al.  Quantitative proton spectroscopy of canine brain: in Vivo and in Vitro correlations , 1994, Magnetic resonance in medicine.

[17]  R. Lenkinski,et al.  The effect of N-acetylaspartate on the intracellular free calcium concentration in NTera2-neurons , 1995, Neuroscience Letters.

[18]  John P. Stack,et al.  1H-magnetic resonance spectroscopy of the left temporal and frontal lobes in schizophrenia: Clinical, neurodevelopmental, and cognitive correlates , 1994, Biological Psychiatry.

[19]  Paul J. Harrison,et al.  Decreased expression of mRNAs encoding non-NMDA glutamate receptors GluR1 and GluR2 in medial temporal lobe neurons in schizophrenia. , 1995, Brain research. Molecular brain research.

[20]  Peter M. G. Munro,et al.  Inhibition of N-acetylaspartate production: implications for 1H MRS studies in vivo. , 1996, Neuroreport.

[21]  J A Frank,et al.  Common pattern of cortical pathology in childhood-onset and adult-onset schizophrenia as identified by proton magnetic resonance spectroscopic imaging. , 1998, The American journal of psychiatry.

[22]  J. Callicott,et al.  The relationship between prefrontal neuronal integrity and striatal amphetamine-induced dopamine activity in patients with schizophrenia , 1998, NeuroImage.

[23]  Daniel R. Weinberger,et al.  Cortical maldevelopment, anti-psychotic drugs, and schizophrenia: a search for common ground , 1995, Schizophrenia Research.

[24]  P. Renshaw,et al.  Temporal lobe proton magnetic resonance spectroscopy of patients with first-episode psychosis. , 1995, The American journal of psychiatry.

[25]  P. Williamson,et al.  The use of a priori knowledge to quantify short echo in vivo 1h mr spectra , 1995, Magnetic resonance in medicine.

[26]  K O Lim,et al.  Proton magnetic resonance spectroscopic imaging of cortical gray and white matter in schizophrenia. , 1998, Archives of general psychiatry.

[27]  M. Bárány,et al.  Proton magnetic resonance spectroscopy of the brain in schizophrenic and affective patients , 1992, Schizophrenia Research.

[28]  B. Miller.  A review of chemical issues in 1H NMR spectroscopy: N‐acetyl‐l‐aspartate, creatine and choline , 1991, NMR in biomedicine.

[29]  N. Lundbom,et al.  Cortical and subcortical chemical pathology in Alzheimer's disease as assessed by multislice proton magnetic resonance spectroscopic imaging , 1996, Neurology.

[30]  Alessandro Bertolino,et al.  Hippocampal N-acetyl aspartate in unaffected siblings of patients with schizophrenia: a possible intermediate neurobiological phenotype , 1998, Biological Psychiatry.

[31]  Alessandro Bertolino,et al.  Reproducibility of Proton Magnetic Resonance Spectroscopic Imaging in Patients with Schizophrenia , 1998, Neuropsychopharmacology.

[32]  M. Weiner,et al.  Decreased left frontal lobe N-acetylaspartate in schizophrenia. , 1997, The American journal of psychiatry.

[33]  M. Maier,et al.  Hippocampal age-related changes in schizophrenia: a proton magnetic resonance spectroscopy study , 1996, Schizophrenia Research.

[34]  N. Schuff,et al.  Proton magnetic resonance spectroscopy of the anterior cingulate region in schizophrenia , 1997, Schizophrenia Research.

[35]  J. Clark,et al.  N-Acetyl Aspartate: A Marker for Neuronal Loss or Mitochondrial Dysfunction , 1998, Developmental Neuroscience.

[36]  Toshiro Inubushi,et al.  Proton magnetic resonance spectroscopy of the basal ganglia in patients with schizophrenia: a preliminary report , 1996, Schizophrenia Research.

[37]  Toshiro Fujimoto,et al.  Proton magnetic resonance spectroscopy of the left medial temporal and frontal lobes in chronic schizophrenia: preliminary report , 1995, Psychiatry Research: Neuroimaging.

[38]  R. Kuzniecky,et al.  Normalization of contralateral metabolic function following temporal lobectomy demonstrated by 1H magnetic resonance spectroscopic imaging , 1996, Annals of neurology.

[39]  S. Potkin,et al.  Selective alterations in gene expression for NMDA receptor subunits in prefrontal cortex of schizophrenics , 1996, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[40]  R G Shulman,et al.  Interpreting functional imaging studies in terms of neurotransmitter cycling. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Tetsuya Takano,et al.  Proton magnetic resonance spectroscopy of basal ganglia in chronic schizophrenia , 1994, Biological Psychiatry.

[42]  J A Frank,et al.  Altered development of prefrontal neurons in rhesus monkeys with neonatal mesial temporo-limbic lesions: a proton magnetic resonance spectroscopic imaging study. , 1997, Cerebral cortex.

[43]  B D Ross,et al.  Metabolic disorders of the brain in chronic hepatic encephalopathy detected with H-1 MR spectroscopy. , 1992, Radiology.

[44]  P Schmalbrock,et al.  Proton Magnetic Resonance Spectroscopy (1H MRS) of the Hippocampal Formation in Schizophrenia: A Pilot Study , 1994, British Journal of Psychiatry.

[45]  J. Moffett,et al.  Differential distribution of N-acetylaspartylglutamate and N-acetylaspartate immunoreactivities in rat forebrain , 1995, Journal of neurocytology.

[46]  Raquel E Gur,et al.  Proton Magnetic Resonance Spectroscopy in the Frontal and Temporal Lobes of Neuroleptic Naive Patients with Schizophrenia , 1999, Neuropsychopharmacology.

[47]  P. Williamson,et al.  An in vivo proton magnetic resonance spectroscopy study of schizophrenia patients. , 1996, Schizophrenia bulletin.

[48]  P. Goldman-Rakic,et al.  Noise stress impairs prefrontal cortical cognitive function in monkeys: evidence for a hyperdopaminergic mechanism. , 1998, Archives of general psychiatry.

[49]  D. Weinberger,et al.  From neuropathology to neurodevelopment , 1995, The Lancet.

[50]  J. Vion-Dury,et al.  Reversal of brain metabolic alterations with zidovudine detected by proton localised magnetic resonance spectroscopy , 1995, The Lancet.

[51]  G. Fein,et al.  Hippocampal neuronal dysfunction in schizophrenia as measured by proton magnetic resonance spectroscopy , 1998, Biological Psychiatry.